Max Healthcare reported an 18% YoY rise in Q2FY27 revenue to Rs 3,055 crore, fueled by higher occupancy and average revenue per bed. Despite a 19.5% dip in net profit, the company is doubling down on expansion with Rs 415 crore approved for new brownfield beds.
Max Healthcare Q2 Results: Revenue Rises 18% to Rs 3,055 Cr
Net Revenue: Rs 3,055 Cr (Up 18% YoY) | Net Profit (Adj): Rs 447 Cr (Down 19.5% YoY)
Reader Takeaway: Strong operational growth driven by bed capacity expansion and higher ARPP offsets margin pressure from brownfield projects.
What just happened
Max Healthcare delivered a mixed quarterly performance for Q2FY27. While top-line revenue grew by 18% to Rs 3,055 crore, the adjusted net profit declined by 19.5% to Rs 447 crore. The revenue surge was backed by a 13% expansion in occupied bed days and an 8% increase in Average Revenue Per Bed (ARPP) to Rs 2.31 lakh. Operating EBITDA rose 18% to Rs 797 crore, maintaining a steady margin of 26.1%.
Why this matters
The company is aggressively scaling its infrastructure. Max Healthcare plans to nearly double its bed capacity over the next 4–5 years. The board has recently approved an additional capital expenditure of Rs 415 crore to add brownfield beds at key locations including Noida, Vaishali, and BLK-Max. Management cites tailwinds from revised CGHS super-specialty tariffs and scheduled annual price revisions in insurance contracts as key future revenue drivers.
Risks to watch
Growth is subject to economic volatility which could dampen patient demand. Furthermore, the healthcare sector faces significant human capital challenges, specifically high doctor attrition rates that may disrupt service quality and revenue. Investors should also monitor the balance sheet as rapid, potentially unplanned, capital expenditure could affect financial leverage.
Peer comparison and valuation
Axis Securities has retained a 'BUY' rating on the stock, issuing a target price of Rs 1,110 per share. This target, based on a 20x EV/EBITDA multiple for FY29E, suggests a potential upside of 24% from the market price as of November 3, 2026.
What to track next
Watch for the successful commissioning of the oncology block at Dwarka and the integration of the newly operationalized brownfield beds at Saket and Nanavati. Sustained occupancy rates above 75% remain critical for long-term margin improvement.